Nav: Home

Double whammy for triple negative breast cancer

December 05, 2016

A promising new combination therapy for a particularly aggressive form of breast cancer has been identified by Weizmann Institute scientists, as was recently reported in Cancer Research. The potential dual-acting therapeutic strategy not only inhibits tumor growth and survival but also circumvents the problem of drug-induced resistance.

Triple negative breast cancer is harder to treat than other types of breast cancer because, as its name suggests, it lacks three receptors that usually serve as targets for anti-cancer drugs. Treatment options are therefore limited to standard chemotherapy, which in many cases proves ineffective.

In their study, Prof. Sima Lev, postdoctoral fellows Drs. Nandini Verma and Anna-Katharina Müller of the Weizmann Institute of Science's Molecular Cell Biology Department and colleagues identified a subset of triple negative breast cancer patients whose tissue samples expressed higher levels of two particular molecules: EGFR and PYK2. EGFR - a cell-surface receptor - has been implicated in a number of cancers when it is overexpressed due to mutations. PYK2 - a robust molecule previously discovered by Lev - plays a key role in breast cancer metastasis.

The scientists found that, in animal models, inhibiting either of these molecules alone led to a slight tumor reduction, but inhibiting them both together resulted in a more potent therapeutic effect, leading to a significant decrease in tumor size.

Upon further investigation, Lev and her team were able to identify the exact molecular pathways and protein interactions in which EGFR and PYK2 involvement leads to tumor growth and survival, and the results appear to explain the potent effect when they are inhibited together. Most strikingly, the team discovered that inhibition of PYK2 not only synergizes with the EGFR inhibitors but could also bypass the problem of resistance to EGFR antagonists.

The reason why inhibiting EGFR alone does not seem to afford much clinical benefit, the scientists believe, is that cells tend to compensate for the lack of EGFR by increasing levels of an alternative receptor molecule called HER3, which is associated with drug resistance to EGFR therapy. The scientists found that inhibiting the second molecule, PYK2, in addition to curtailing cancer growth and metastasis, also sets in motion an additional chain of events that ultimately marks HER3 for degradation. Helping to rid the cells of HER3 allows EGFR therapy to work more effectively.

We believe that this combination therapy - targeting both EGFR and PYK2 - provides a promising, more effective approach for a subset of triple negative breast cancer patients than other combinations that are currently being tested, owing to its ability to impede tumor growth and survival and prevent drug resistance," says Lev.

About one-fifth of all breast cancers are triple negative, which means that more than 300,000 women worldwide are diagnosed every year with this form of malignancy.
-end-
Prof. Sima Lev's research is supported by the Benoziyo Fund for the Advancement of Science; the Miriam and Luis Stillmann Laboratory; the Dr. Dvora and Haim Teitelbaum Endowment Fund; the Steven B. Rubenstein Research Fund for Leukemia and Other Blood Disorders; Foundation Adelis; the Rising Tide Foundation; Lord David Alliance, CBE; and David E. and Sheri Stone, Coral Gables, FL. Prof. Lev is the incumbent of the Joyce and Ben B. Eisenberg Professorial Chair of Molecular Endocrinology and Cancer Research.The Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to scientists, students, technicians and supporting staff. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new strategies for protecting the environment.

Weizmann Institute of Science

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.